Dr. Anne Klibanski M.D. is the Independent Director of Albireo Pharma Inc. Dr. Klibanski has served as President and Chief Executive Officer of Partners HealthCare since June 2019. She previously served as Chief Academic Officer of Partners HealthCare from April 2012 to November 2019, where she oversaw Partners-wide academic programs in research and education. Dr. Klibanski has also served as Chief, Neuroendocrine Unit at Massachusetts General Hospital since 1989 and as the Laurie Carrol Guthart Professor of Medicine at Harvard Medical School since 2009. She is a leader in the field of neuroendocrine disorders and pituitary tumors. The author of over 350 papers and chapters, she has received numerous awards, including the Endocrine Society Clinical Investigator Award and the Clinical Endocrinology Trust Medal from the British Endocrine Society and has served as a member of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Board of Counselors. Dr. Klibanski holds a B.A. from Barnard College and an M.D. from New York University School of Medicine.
As the Independent Director of Albireo Pharma Inc, the total compensation of Anne Klibanski at Albireo Pharma Inc is $160,565. There are 13 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.
Anne Klibanski is 69, he's been the Independent Director of Albireo Pharma Inc since 2018. There are 1 older and 18 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
Anne's mailing address filed with the SEC is Ten Post Office Square, Boston, MA 02109, USA.
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs a Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Inc executives and other stock owners filed with the SEC include: